Re: The association between statins and cancer incidence in a veterans population [2]

Journal of the National Cancer Institute

Volumn 100, Issue 13, 2008, Pages 972-973

  Ravnskov, Uffe ^a  

^a NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN; ANTINEOPLASTIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CARCINOGENICITY; CLINICAL TRIAL; FOLLOW UP; HUMAN; LETTER; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; SKIN CANCER; VETERAN; COLORECTAL TUMOR; EPIDEMIOLOGY; INCIDENCE; LUNG TUMOR; MALE; NEOPLASM; NOTE; PROSTATE TUMOR; STATISTICS; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LUNG NEOPLASMS; MALE; NEOPLASMS; PRAVASTATIN; PROSTATIC NEOPLASMS; SIMVASTATIN; UNITED STATES; VETERANS;

EID: 46849085768     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn160     Document Type: Letter

References (7)

1. Scandinavian Simvastatin Survival Study Group. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100(2):134-139.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
3. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
4. Iwata H, Matsuo K, Hara S, et al. Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci. 2006;97(2):133-138.
5. Sacks FM, Pfeffer MA, Moye LA, et al.; for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001-1009.
6. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vas cular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(946):1623-1630.
7. Matsuzaki M, Kita T, Mabuchi H, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J. 2002(12);66:1087-1095.